North America Vacuum Blood Collection Tube Market Size, Share & Trends Analysis Report By Product Type (Serum Tubes, Plasma Separation Tubes, Heparin Tubes, EDTA Tubes), By Material (Plastic, Glass), By Country (U.S., Canada) and Forecast, 2026-2034

North America Vacuum Blood Collection Tube Market Trends

Shift Toward Safer Collection, Plastic Formats and Pre-analytical Standardization

Laboratories are increasingly prioritizing specimen integrity, safety closures, automation compatibility, and standardized additive-to-blood ratios. BD reports that up to 70% of clinical decisions rely on laboratory-test information and that incorrect fill volume contributes to specimen rejection in 10–20% of affected cases. Its product evaluation also references a survey of 225 laboratory professionals, highlighting the importance of analytical accuracy and sample quality.

Technology is moving beyond conventional evacuated containers toward safety-engineered collection sets, specialized separators, molecular-diagnostic stabilization, and workflow automation. In 2025, Greiner Bio-One reported EUR 637 million in revenue, 2,651 employees and 28 locations while highlighting its VACUETTE EVOPROTECT safety collection technology. SARSTEDT's DNA Exact platform supports whole-blood storage for at least 14 days at room temperature and 28 days at 4°C, illustrating growing demand for specialized pre-analytical preservation.

North America Vacuum Blood Collection Tube Market Drivers

High Diagnostic Testing Intensity and Chronic Disease Burden

High laboratory utilization remains a structural demand driver. Approximately 70% of clinical decisions can depend on laboratory-derived information, while about 12 million U.S. adults are affected by outpatient diagnostic errors annually. The American Hospital Association count cited in industry research indicates approximately 6,093 U.S. hospitals, while about 2.0 million new U.S. cancer cases were estimated for 2025. These volumes sustain recurring requirements for chemistry, hematology and disease-monitoring specimens.

North America Vacuum Blood Collection Tube Market Restraints

Pre-analytical Errors and Procurement Pressure Restrain Adoption

Tube performance depends on correct filling, additives, centrifugation, storage and handling. Incorrect tube-fill volume can account for specimen rejection in 10–20% of cases, creating redraw costs and delayed results. Manufacturers simultaneously manage numerous configurations: SARSTEDT, for example, lists 35 serum, 41 heparin, 21 citrate, 37 EDTA and 14 glucose-determination S-Monovette variants, increasing inventory and qualification complexity for healthcare purchasers.

North America Vacuum Blood Collection Tube Market Opportunities

Specialized Molecular Diagnostics and Automated Pre-analytics Expand Addressable Use

Special-purpose tubes create opportunities beyond routine chemistry. SARSTEDT reports DNA preservation for at least 14 days at room temperature, 28 days at 4°C and at least 3 months at -20°C, with up to 5 freeze/thaw cycles evaluated. Meanwhile, safety-engineered systems target occupational exposure: BD states its UltraTouch push-button technology can reduce needlestick-injury risk by 88%, supporting premium adoption in high-throughput collection environments.

Challenges in North America Vacuum Blood Collection Tube Market

Maintaining Standardization Across Large Tube Portfolios

Clinical laboratories must balance analyzer compatibility, additive concentration, draw volume, cap coding and regulatory compliance. Individual products can differ materially: a SARSTEDT EDTA tube specifies 1.3 mL volume and 1.6 mg/mL K3 EDTA, while packaging contains 100 units per inner box and 1,000 per outer case. ISO 6710:2017 recommendations further reinforce the operational requirement for standardized blood-collection color coding.

North America Vacuum Blood Collection Tube Market Segmentation

The industry is segmented by product type, material, application, end user and distribution channel. Product data show serum tubes commanding approximately 30.8% of 2026 revenue, followed by plasma separation tubes at approximately 21.8%.

By Product Type

Serum tubes lead with USD 323.08 million in 2026 and are forecast to reach USD 428.07 million by 2034 at 3.58% CAGR. Plasma separation tubes follow at USD 228.70 million in 2026 and USD 298.60 million in 2034, with 3.39% CAGR.

ESR tubes record the fastest listed CAGR at 3.62%, rising from USD 105.14 million in 2026 to USD 139.74 million in 2034. Heparin tubes grow at 3.21%, EDTA tubes at 3.26%, glucose tubes at 3.16%, and Others at 3.58%.

By Material

The market is divided between plastic and glass tubes. Plastic increasingly aligns with high-throughput workflows because of breakage resistance, lower handling risk and compatibility with automated pre-analytics.

The supplied mandatory dataset does not provide material-level revenue or CAGR; therefore, no unsupported market size or growth percentage is assigned to plastic or glass.

By Application

Applications include routine chemistry, blood sugar testing, coagulation testing, lipid profile, infectious disease testing and others. Routine chemistry benefits particularly from serum and plasma-based workflows.

Application-level market values and CAGRs are not provided in the mandatory dataset. Consequently, numerical revenue or CAGR attribution across the 6 application categories is not fabricated.

By End User

Hospitals, diagnostic laboratories, blood banks, ambulatory surgical centers and academic/research facilities constitute the 5 principal end-user categories, with recurring testing supporting high tube turnover.

The supplied dataset contains no end-user revenue or CAGR figures. External evidence nevertheless indicates approximately 6,093 U.S. hospitals, illustrating the scale of the institutional customer base.

By Distribution Channel

Direct tender, retail sales, online sales and distributors form the 4-channel structure. Large hospital systems typically emphasize contracted procurement, while laboratories and smaller facilities can use distributor-led replenishment.

No channel-level revenue, percentage contribution or CAGR is supplied; accordingly, the 4 distribution channels are presented without unsupported quantitative allocation.

North America Vacuum Blood Collection Tube Market Counties Outlook

U.S.

The U.S. generates USD 735.08 million in 2026, approximately 70.1% of the North American country total, compared with USD 711.18 million in 2025. Revenue is forecast to reach USD 957.53 million by 2034 at 3.36% CAGR, adding USD 222.45 million from 2026.

Demand is supported by hospitals, reference laboratories and outpatient diagnostics. With approximately 6,093 hospitals and an estimated 2.0 million new cancer cases in 2025, the country maintains a large recurring specimen-testing ecosystem.

Canada

Canada increases from USD 303.48 million in 2025 to USD 313.92 million in 2026 and USD 411.46 million by 2034. Its approximately 29.9% 2026 contribution is smaller than the U.S., but its 3.44% CAGR exceeds the U.S. rate by 0.08 percentage points.

The USD 97.54 million incremental opportunity between 2026 and 2034 reflects continued laboratory modernization, centralized procurement and demand across hospitals, diagnostic laboratories and blood-service infrastructure.

Top players in North American vacuum blood collection tube market

1. Becton, Dickinson and Company
2. Greiner Bio-One International GmbH
3. SARSTEDT AG & Co. KG
4. Terumo Corporation
5. Cardinal Health, Inc.
6. SEKISUI Medical Co., Ltd.
7. Nipro Corporation
8. Streck, Inc.
9. Zhejiang Gongdong Medical Technology Co., Ltd.
10. FL Medical S.r.l.
11. AdvaCare Pharma
12. Hindustan Syringes & Medical Devices Ltd.
13. Q-Sera Pty Ltd.
14. Tasso, Inc.
15. Improve Medical Instruments Co., Ltd.

Top Two Companies

• Becton, Dickinson and Company:BD holds the leading competitive position according to industry assessments, although a verified standalone North American tube-only percentage is not publicly disclosed. A broader blood-collection-device assessment places the top 3 suppliers collectively at 49.9%. BD's competitive strength rests on the Vacutainer portfolio, analyzer compatibility and extensive pre-analytical solutions. The company marked 75 years of Vacutainer technology in 2024, while FDA clearance BK230980 for K2EDTA tubes was issued on April 17, 2024.
• Greiner Bio-One International GmbH:Greiner forms part of the industry's leading supplier tier; no defensible North America-specific standalone percentage is publicly disclosed. The broader top-3 supplier group is estimated at 49.9%. Greiner Bio-One reported EUR 637 million revenue, 2,651 employees and 28 locations in 2025. Its VACUETTE platform and EVOPROTECT safety technology strengthen positioning in hospitals and laboratories seeking standardized collection, safety mechanisms and pre-analytical reliability.

Recent Developments in the North American Vacuum Blood Collection Tube Market

• 2025: Greiner Bio-One highlighted VACUETTE EVOPROTECT, featuring a semi-automatic click mechanism designed to minimize needlestick risk.
• 2025: SARSTEDT documented its IVD-certified S-Monovette DNA Exact, demonstrating whole-blood DNA stability for 14 days at room temperature and 28 days at 4°C.

Research Methodology

The analysis uses 2025 as the base year, 2026 as the current year and 2026–2034 as the forecast period, supported by historical context from 2022–2024. Mandatory supplied country and product-type datasets are treated as the primary quantitative source. Shares are calculated directly from supplied totals—for example, USD 735.08 million divided by USD 1,049.00 million yields approximately 70.1% U.S. contribution in 2026, while USD 323.08 million divided by USD 1,049.44 million yields approximately 30.8% for serum tubes. Secondary validation uses company publications, FDA records and industry sources; figures unavailable in the mandatory dataset are not fabricated.